(Q36872938)

16 August 2017

1 reference

title

Scientific and policy challenges to development of an AIDS vaccine (English)

1 reference

16 August 2017

Seth Franklin Berkley

series ordinal

1

1 reference

PubMed ID

17617277

16 August 2017

Wayne Chester Koff

series ordinal

2

1 reference

PubMed ID

17617277

16 August 2017

language of work or name

English

0 references

publication date

1 July 2007

1 reference

16 August 2017

1 reference

16 August 2017

370

1 reference

16 August 2017

94-101

1 reference

16 August 2017

9581

1 reference

Integrating HIV prevention and treatment: from slogans to impact

16 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

The impact of an AIDS vaccine in developing countries: a new model and initial results.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

HIV vaccine design: insights from live attenuated SIV vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Characterization of three nef-defective human immunodeficiency virus type 1 strains associated with long-term nonprogression. Australian Long-Term Nonprogressor Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Pseudotyped single-cycle simian immunodeficiency viruses expressing gamma interferon augment T-cell priming responses in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Transient early post‐inoculation anti‐retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut‐associated lymphoid tissues in SIVmac239‐infected rhesus macaques, but not resistance to rechallenge

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Induction of a virus-specific effector-memory CD4+ T cell response by attenuated SIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Public health. A sound rationale needed for phase III HIV-1 vaccine trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

HIV vaccine design and the neutralizing antibody problem

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Defining the Protective Antibody Response for HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

GP120: target for neutralizing HIV-1 antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Structural definition of a conserved neutralization epitope on HIV-1 gp120

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Potential public health impact of imperfect HIV type 1 vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

HIV diversity, molecular epidemiology, and the role of recombination.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Evolutionary and immunological implications of contemporary HIV-1 variation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Evaluation of cellular immune responses in subjects chronically infected with HIV type 1

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

CD8+ T-cell responses to different HIV proteins have discordant associations with viral load

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

Perils at mucosal front lines for HIV and SIV and their hosts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961054-X

7 January 2021

10.1016/S0140-6736(07)61054-X

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17617277